1 | J01GB01 | - | - | - | - | 1件: 299 299 💬
|
2 | J05A F01 | - | - | - | - | 1件: 135 135 💬
|
3 | J05AG04 | - | - | - | - | 1件: 18 18 💬
|
4 | J07AH07 | - | - | - | - | 1件: 14 14 💬
|
5 | J1081 | - | - | - | - | 1件: 56 56 💬
|
6 | J695 | - | - | - | - | 1件: 96 96 💬
|
7 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬
|
8 | JAK 3 | - | - | - | - | 1件: 46 46 💬
|
9 | JAK 3 Ritlecitinib | - | - | - | - | 1件: 46 46 💬
|
10 | JAK inhibitor | - | - | - | - | 2件: 46 46, 50 💬
|
11 | JAK1 / JAK2 Inhibitor | - | - | - | - | 1件: 46 46 💬
|
12 | JAK1 / JAK2 Inhibtor | - | - | - | - | 1件: 46 46 💬
|
13 | JAKi | - | - | - | - | 1件: 46 46 💬
|
14 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬
| - | - | 1件: 85 85 💬
|
15 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬
| - | - | 1件: 85 85 💬
|
16 | Jaktinib Hydrochloride Tablets | - | - | - | - | 1件: 271 271 💬
|
17 | Janus Kinase Inhibitor | - | - | - | - | 2件: 46 46, 97 💬
|
18 | Jardiance | 1件: Empagliflozin Empagliflozin | 1件: Empagliflozin
Empagliflozin
💬
| 1件: SLC5A2 SLC5A2 💬
| - | 1件: 65 65 💬
|
19 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 💬
|
20 | JBT-101 (lenabasum) | - | - | - | - | 1件: 299 299 💬
|
21 | JBT101 | - | - | - | - | 1件: 299 299 💬
|
22 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬
|
23 | Jevity 1.5 | - | - | - | - | 1件: 2 2 💬
|
24 | JHL1101 | - | - | - | - | 1件: 46 46 💬
|
25 | Jianpixiaozhong particles and Wuse Dietotherapy | - | - | - | - | 1件: 222 222 💬
|
26 | Jinarc | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
27 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
28 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
29 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
30 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
31 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
32 | Jinarc - Tolvaptan tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
33 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
34 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
35 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
36 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
37 | Jinarc® 15mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
38 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬
| 1件: AVPR2 AVPR2 💬
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬
|
39 | Jintropin AQ | - | - | - | - | 1件: 78 78 💬
|
40 | JKB-122 | - | - | - | - | 1件: 95 95 💬
|
41 | JKB-122 in capsule or tablet form | - | - | - | - | 1件: 95 95 💬
|
42 | JM | - | - | - | - | 2件: 6 6, 13 💬
|
43 | JM-010 | - | - | - | - | 1件: 6 6 💬
|
44 | JM-4 | - | - | - | - | 1件: 13 13 💬
|
45 | JNJ 38518168 | - | - | - | - | 1件: 46 46 💬
|
46 | JnJ 54767414 | - | - | - | - | 1件: 28 28 💬
|
47 | JNJ-16240159-AAC | - | - | - | - | 1件: 46 46 💬
|
48 | JNJ-31001074 | - | - | - | - | 1件: 6 6 💬
|
49 | JNJ-38518168 | - | - | - | - | 1件: 46 46 💬
|
50 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 💬
|
51 | JNJ-38518168 (3 mg) | - | - | - | - | 1件: 46 46 💬
|
52 | JNJ-38518168 (30 mg) | - | - | - | - | 1件: 46 46 💬
|
53 | JNJ-38518168 / MTX | - | - | - | - | 1件: 46 46 💬
|
54 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 💬
|
55 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 💬
|
56 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 💬
|
57 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬
|
58 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 💬
|
59 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 💬
|
60 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬
|
61 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 💬
|
62 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 💬
|
63 | JNJ-39039039 | - | - | - | - | 1件: 210 210 💬
|
64 | JNJ-39758979 | - | - | - | - | 1件: 46 46 💬
|
65 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 💬
|
66 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 💬
|
67 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 💬
|
68 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 💬
|
69 | JNJ-39758979 / MTX | - | - | - | - | 1件: 46 46 💬
|
70 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬
|
71 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 💬
|
72 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 💬
|
73 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 💬
|
74 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬
|
75 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 💬
|
76 | JNJ-42160443 | - | - | - | - | 1件: 226 226 💬
|
77 | JNJ-54767414 | - | - | - | - | 2件: 28 28, 49 💬
|
78 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 💬
|
79 | JNJ-54781532 25 mg once daily | - | - | - | - | 1件: 97 97 💬
|
80 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 💬
|
81 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 💬
|
82 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 💬
|
83 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 💬
|
84 | JNJ-54781532-AAD-5 mg | - | - | - | - | 1件: 97 97 💬
|
85 | JNJ-55920839 | - | - | - | - | 1件: 49 49 💬
|
86 | JNJ-56022473 | - | - | - | - | 1件: 49 49 💬
|
87 | JNJ-64304500 | - | - | - | - | 1件: 96 96 💬
|
88 | JNJ-64304500-AAA | - | - | - | - | 1件: 96 96 💬
|
89 | JNJ-64841829 | - | - | - | - | 1件: 97 97 💬
|
90 | JNJ-64841842 | - | - | - | - | 1件: 97 97 💬
|
91 | JNJ-64841855 | - | - | - | - | 1件: 97 97 💬
|
92 | JNJ-64841894 | - | - | - | - | 1件: 97 97 💬
|
93 | JNJ-64841907 | - | - | - | - | 1件: 97 97 💬
|
94 | JNJ-64841920 | - | - | - | - | 1件: 97 97 💬
|
95 | JNJ-64841933 | - | - | - | - | 1件: 97 97 💬
|
96 | JNJ-64841946 | - | - | - | - | 1件: 97 97 💬
|
97 | JNJ-66525433 | - | - | - | - | 1件: 97 97 💬
|
98 | JNJ-67484703 | - | - | - | - | 1件: 46 46 💬
|
99 | JNJ-67864238 | - | - | - | - | 1件: 96 96 💬
|
100 | JNJ-67896049 | - | - | - | - | 1件: 86 86 💬
|
101 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 💬
|
102 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬
|
103 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬
|
104 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬
|
105 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬
|
106 | JNJ-72537634 | - | - | - | - | 1件: 97 97 💬
|
107 | JNJ-78934804 | - | - | - | - | 2件: 96 96, 97 💬
|
108 | JNJ-80202135 | - | - | - | - | 4件: 11 11, 46, 49, 53 💬
|
109 | JNJ31-31001074 | - | - | - | - | 1件: 6 6 💬
|
110 | Joint puncture | - | - | - | - | 1件: 107 107 💬
|
111 | Jojoba oil | 1件: Jojoba oil Jojoba oil | - | - | - | 1件: 36 36 💬
|
112 | Jojoba oil with broccoli sprout extract | 2件: Broccoli Broccoli, Jojoba oil | - | - | - | 1件: 36 36 💬
|
113 | Jorveza | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬
|
114 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬
|
115 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬
|
116 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬
|
117 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬
|
118 | JP 1730 | - | - | - | - | 1件: 6 6 💬
|
119 | JP-1730/F01 | - | - | - | - | 2件: 6 6, 17 💬
|
120 | JP-1730/F02 | - | - | - | - | 2件: 6 6, 17 💬
|
121 | JP-1730/F03 | - | - | - | - | 2件: 6 6, 17 💬
|
122 | JR-141 | - | - | - | - | 1件: 19 19 💬
|
123 | JR-141 or Idursulfase | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬
| 1件: IDS IDS 💬
| 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬
|
124 | JR-171 (lepunafusp alfa) | - | - | - | - | 1件: 19 19 💬
|
125 | JS002 | - | - | - | - | 1件: 79 79 💬
|
126 | JS005 | - | - | - | - | 1件: 271 271 💬
|
127 | JSP191 | - | - | - | - | 2件: 65 65, 285 💬
|
128 | JTE-051 | - | - | - | - | 1件: 46 46 💬
|
129 | JTT-251 | - | - | - | - | 1件: 86 86 💬
|
130 | Juanbi pill | - | - | - | - | 1件: 46 46 💬
|
131 | Juvit D3 | - | - | - | - | 1件: 6 6 💬
|
132 | Jyseleca | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬
| 1件: JAK1 JAK1 💬
| 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬
|
133 | Jyseleca 100 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬
| 1件: JAK1 JAK1 💬
| 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬
|
134 | Jyseleca 200 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬
| 1件: JAK1 JAK1 💬
| 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬
|
135 | JZP-110 | - | - | - | - | 1件: 6 6 💬
|